Stocktoria
RECURSION PHARMACEUTICALS, INC. RXRX
RECURSION PHARMACEUTICALS, INC. (RXRX) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $74.7M at a -863.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.451 |
| Retained earnings / assets | -1.408 |
| EBIT / assets | -0.44 |
| Equity / liabilities | 3.294 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RXRX | RECURSION PHARMACEUTICALS, INC. | 3/9 | -1.13 | — | +26.9% |
| AUTL | Autolus Therapeutics plc | 2/9 | -6.27 | — | +644.9% |
| CGEN | COMPUGEN LTD | 6/9 | -0.84 | 5.6 | +161.1% |
| BDTX | Black Diamond Therapeutics, Inc. | 6/9 | -0.83 | 4.4 | — |
| VIR | Vir Biotechnology, Inc. | 2/9 | -0.97 | — | -7.6% |
| MGTX | MeiraGTx Holdings plc | 2/9 | -14.65 | — | +144.6% |
| FDMT | 4D Molecular Therapeutics, Inc. | 3/9 | 6.96 | — | — |
About RECURSION PHARMACEUTICALS, INC.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
FAQ
Is RXRX financially healthy?
RECURSION PHARMACEUTICALS, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does RXRX pay a dividend?
No, RECURSION PHARMACEUTICALS, INC. does not currently pay a dividend.
How profitable is RXRX?
In FY2025, RECURSION PHARMACEUTICALS, INC. had a net margin of -863.4% and a return on equity of -57.0%.
What is the analyst price target for RXRX?
The average Wall-Street price target for RECURSION PHARMACEUTICALS, INC. is $6.64, about 101.9% above the recent price, from 7 analysts.
Is RXRX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on RECURSION PHARMACEUTICALS, INC.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.